CELLTRION, INC.

Sector Chart Celltrion, Inc.

Equities

A068270

KR7068270008

End-of-day quote Korea S.E. Other stock markets 09/09/2024			5-day change	1st Jan Change
192,100.00 ^KRW	+0.47%		-2.54%	-4.67%

08-29	Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	CI
08-26	European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Sector Other Biotechnology & Medical Research

	Capi.	Sales growth	Profitability	Finances	EV / Sales	P/E ratio
CELLTRION, INC.	29.51B
LONZA GROUP AG	46.26B
IQVIA HOLDINGS INC.	43.91B
ALNYLAM PHARMACEUTICALS, INC.	32.5B					-
MODERNA, INC.	29.45B					-
ICON PUBLIC LIMITED COMPANY	24.74B

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW